3 Dividend Stocks to Buy to Help Soothe Some of Your Pain

NYSE: PFE | Pfizer Inc. News, Ratings, and Charts

PFE – Although inflation eased slightly last month, the Fed has indicated that the final level of interest rates could be higher than expected. With further interest rate hikes and the possibility of a recession expected to keep the market under pressure, it could be wise to buy dividend-paying stocks Pfizer (PFE), LSI Industries (LYTS), and Spok Holdings (SPOK) to generate a steady income stream. Read more….

The Federal Reserve recently raised its short-term borrowing rate by 75 basis points to a target range of 3.75%-4%, the highest since January 2008. High borrowing costs and inflation continue to worry investors about a possible recession.

While dealing with many economic headwinds and market volatility, investors might make emotionally charged investment decisions that may be irrational. In a deteriorating macroeconomic climate, dividends can help generate a stable income and provide a buffer against inflation.

Investors’ interest in dividend stocks is evident from the SPDR S&P Dividend ETF (SDY) 12.8% returns over the past month.

Therefore, it could be wise to invest in fundamentally strong stocks Pfizer Inc. (PFE), LSI Industries Inc. (LYTS), and Spok Holdings, Inc. (SPOK), which have an impressive track record of dividend payments.

Pfizer Inc. (PFE)

PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health, biosimilars, sterile injectable and anti-infective medicines, and oral COVID-19 treatment.

Over the last three years, PFE’s dividend payouts have grown at a 5.5% CAGR. Its four-year average dividend yield is 3.6%, and its forward annual dividend of $1.60 per share translates to a 3.36% yield. The company grew its dividend payments for 12 consecutive years.

On October 03, 2022, PFE announced its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy. The acquisition is believed to strengthen Pfizer’s innovative Internal Medicine pipeline through 2030, bringing new treatment options to patients suffering from migraines.

For the fiscal third quarter ended October 2, 2022, PFE’s total assets increased 7.6% to $195.35 billion, compared to $181.48 billion for the fiscal year ended December 31, 2021. The company’s adjusted net income increased 39.7% year-over-year to $10.17 billion. Its non-GAAP EPS came in at $1.78, representing a 40.2% increase from the prior-year quarter.

PFE’s EPS and revenue for the quarter ending December 31, 2022, are expected to increase 1% and 1.9% year-over-year to $1.09 and $24.29 billion, respectively. It has an impressive earnings surprise history, surpassing its consensus EPS estimates in each of the trailing four quarters. The stock has gained 13.6% over the past month to close the last trading session at $47.60.

PFE’s POWR Ratings reflect its solid growth prospects. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

Within the Medical – Pharmaceuticals industry, it is ranked #3 out of 162 stocks. The company has an A grade for Value and a B for Growth and Quality. Click here to see the additional POWR Ratings of PFE for Momentum, Stability, and Sentiment.

LSI Industries Inc. (LYTS)

LYTS produces and sells non-residential lighting and retail display solutions in the United States, Canada, Mexico, Australia, and Latin America. It operates in two segments, Lighting and Display Solutions.

LYTS’ four-year average dividend yield is 3.5%, and its forward annual dividend of $0.20 per share translates to a 1.99% yield. The company paid dividends for 17 consecutive years.

LYTS’ net sales for the first quarter ended September 30, 2022, increased 19% year-over-year to $127.07 million. Its adjusted operating income increased 117.7% from the prior-year quarter to $10.89 million.

The company’s adjusted net income increased 99.9% year-over-year to $7.08 million. Its adjusted EBITDA increased 76% year-over-year to $13.31 million, while its non-GAAP EPS came in at $0.25, representing a 92.3% increase from the prior-year quarter.

Analysts expect LYTS’ EPS and revenue for the quarter ending December 31, 2022, to increase 54.6% and 6.6% year-over-year to $0.17 and $118.44 million, respectively. It has a commendable earnings surprise history, surpassing the consensus EPS estimates in each of the trailing four quarters. The stock has gained 46.5% year-to-date to close the last trading session at $10.05.

LYTS’ positive outlook is reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. It is ranked first out of 89 stocks in the Industrial – Equipment industry. It has an A grade for Value and Sentiment and a B for Growth and Quality.

We have also given LYTS grades for Momentum and Stability. Get all LYTS ratings here.

Spok Holdings, Inc. (SPOK)

SPOK provides healthcare communication solutions worldwide. It delivers clinical information to care teams to enhance patient outcomes. The company offers subscriptions to one-way or two-way messaging services and ancillary services and sells devices to resellers. In addition, the company provides professional software license updates and product support services, as well as sells third-party equipment.

Over the last three years, SPOK’s dividend payouts grew at a 28.6% CAGR. Its four-year average dividend yield is 5.9%, and its forward annual dividend of $1.25 per share translates to a 14.38% yield. The company paid dividends for 12 consecutive years.

On April 25, 2022, SPOK announced that through its strong partnership with Tyto Athene, it would provide maintenance, support, and professional services for its communications solutions at 48 United States Air Force, Air National Guard, Air Force Reserve, and Space Force bases globally.

Vincent D. Kelly, president and CEO of Spok Holdings, Inc., said, “As we enter our eighth year of providing these life safety systems at bases across the globe, we consider it a privilege to continue our support for such a crucial division in our country’s defense system.”

SPOK’s net income for the third quarter ended September 30, 2022, increased 217.1% year-over-year to $2.92 million. The company’s adjusted operating expenses declined 29.2% year-over-year to $27.87 million. Its adjusted EBITDA increased 286.6% year-over-year to $4.66 million. In addition, its net EPS increased 215.4% from the year-ago period to $0.15.

For the quarter ending June 30, 2023, SPOK’s EPS is expected to increase 40% year-over-year to $0.14. Over the past six months, the stock has gained 21.9% to close the last trading session at $8.69.

SPOK’s strong fundamentals are reflected in its POWR Ratings. The company has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. It is ranked first out of 20 stocks in the Telecom – Domestic industry. In addition, it has an A grade for Growth and a B for Sentiment and Quality.

Click here to see the other ratings of SPOK for Value, Momentum, and Stability.


PFE shares fell $0.10 (-0.21%) in premarket trading Monday. Year-to-date, PFE has declined -16.77%, versus a -15.12% rise in the benchmark S&P 500 index during the same period.


About the Author: Dipanjan Banchur


Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master’s degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
PFEGet RatingGet RatingGet Rating
LYTSGet RatingGet RatingGet Rating
SPOKGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

What is “Active Investing”?

Long term investing is not an easy path to top the stock market (SPY). On the other hand most active trading approaches miss some key elements that lead to outperformance. So let’s talk about a best of both worlds approach called “Active Investing”. Read on below for more...

:  |  News, Ratings, and Charts

The 5 Best Stocks to Invest in for the Long Term

Despite current market uncertainties, the U.S. economy's long-term growth prospects are pretty viable. Experts believe inflation will fall dramatically in the coming year, and robust growth will follow. Therefore, investors could buy quality stocks Microsoft (MSFT), Vertex Pharmaceuticals (VRTX), Centene (CNC), Agilent Technologies (A), and Myers Industries (MYE), which seem poised for steady long-term growth. Keep reading…

:  |  News, Ratings, and Charts

1 Chip Stock Warren Buffett Just Bought

Warren Buffet recently purchased shares of chip giant Taiwan Semiconductor (TSM) worth more than $4 billion. The company enjoys a leadership position in the field of advanced semiconductors. However, is it well-positioned to survive the economic and industry-specific challenges now? Read on to find out…

:  |  News, Ratings, and Charts

The 3 Most Stable Stocks to Buy in This Crazy Market

Even though the most recent inflation data shows signs of cooling down, the Fed will likely continue raising rates to meet its target. Moreover, the weakening profit outlook for the fourth quarter only adds to the recession worries. Hence, fundamentally strong and stable stocks PepsiCo (PEP), Cisco Systems (CSCO), and Sprouts Farmers Market (SFM) might be solid buys in this crazy scenario. Continue reading...

:  |  News, Ratings, and Charts

1 Chip Stock Warren Buffett Just Bought

Warren Buffet recently purchased shares of chip giant Taiwan Semiconductor (TSM) worth more than $4 billion. The company enjoys a leadership position in the field of advanced semiconductors. However, is it well-positioned to survive the economic and industry-specific challenges now? Read on to find out…

Read More Stories

More Pfizer Inc. (PFE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PFE News